[1] Type 2 diabetes and its complications also pose enormous health and economic burdens, [2, 3] especially with respect to outpatient settings and prescription expenditures.[4] Given the progressive nature of type 2 diabetes, many patients eventually will be treated with insulin, which accounts for a large and increasing proportion of treatment expenditures.[5]. This evidence concerns the gene INS and type 2 diabetes mellitus.